ATE334664T1 - Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung - Google Patents

Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung

Info

Publication number
ATE334664T1
ATE334664T1 AT00982276T AT00982276T ATE334664T1 AT E334664 T1 ATE334664 T1 AT E334664T1 AT 00982276 T AT00982276 T AT 00982276T AT 00982276 T AT00982276 T AT 00982276T AT E334664 T1 ATE334664 T1 AT E334664T1
Authority
AT
Austria
Prior art keywords
cell
inflammatory reactions
inhibiting inflammatory
delivery
cells
Prior art date
Application number
AT00982276T
Other languages
English (en)
Inventor
Jack J Hawiger
Daniel Robinson
Ruth Ann Veach
Xue Yan Liu
Danya Liu
Sheila Timmons
Robert D Collins
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE334664T1 publication Critical patent/ATE334664T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00982276T 1999-11-29 2000-11-29 Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung ATE334664T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/450,071 US6495518B1 (en) 1994-06-13 1999-11-29 Method for importing biologically active molecules into cells

Publications (1)

Publication Number Publication Date
ATE334664T1 true ATE334664T1 (de) 2006-08-15

Family

ID=23786649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982276T ATE334664T1 (de) 1999-11-29 2000-11-29 Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung

Country Status (10)

Country Link
US (2) US6495518B1 (de)
EP (1) EP1246616B1 (de)
JP (1) JP2003514852A (de)
KR (1) KR20030025901A (de)
AT (1) ATE334664T1 (de)
AU (1) AU783479B2 (de)
BR (1) BR0015977A (de)
CA (1) CA2391943A1 (de)
DE (1) DE60029829T2 (de)
WO (1) WO2001037821A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
WO2003064614A2 (en) * 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
GB0207624D0 (en) * 2002-04-02 2002-05-15 Cancer Res Ventures Ltd Chemokine and uses thereof
EP2418219B1 (de) 2003-10-17 2018-06-27 InterK Peptide Therapeutics Limited Verfahren und wirkstoffe zur behandlung von krebs
US8080251B2 (en) * 2004-07-21 2011-12-20 Centre For Dna Fingerprinting And Diagnostics Antigenic peptides
JP2008519839A (ja) * 2004-11-09 2008-06-12 セルテック バイオサイエンス エルエルシー 癌細胞におけるアポトーシスの増加のための組成物および方法
CA2605160A1 (en) 2005-04-05 2006-10-05 Allergan, Inc. Clostridial toxin activity assays
US7517959B2 (en) * 2005-11-11 2009-04-14 Walter And Eliza Hall Institute Of Medical Research SOCS3 proteins
JP2009536670A (ja) * 2006-05-10 2009-10-15 スミスクライン・ビーチャム・コーポレイション 化合物の細胞浸透性を増加させるための組成物および方法
EP2185707B1 (de) * 2007-09-04 2013-07-03 Procell Therapeutics Inc. Zelldurchlässige rekombinante nm23-proteine, polynukleotide zu deren kodierung und anti-krebsmetastasen-zusammensetzung damit
KR100887266B1 (ko) * 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
KR20100056508A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 폐렴 연쇄상 구균 감염의 치료를 위한 ｂｆｇｆ １－２４ 및 임의의 （ａｒｇ ８）바소프레신의 용도
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
JP2012533521A (ja) 2008-07-17 2012-12-27 ニュートリペップ・ピーティーワイ・リミテッド 治療剤
BRPI1008940A2 (pt) 2009-03-13 2020-10-27 Allergan, Inc. linhagem de célula clonal estabelecida suscetível à intoxicação por bont/a
KR101923847B1 (ko) 2009-03-13 2018-11-29 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정
KR101122845B1 (ko) * 2009-07-30 2012-03-21 부산대학교 산학협력단 경구용 염증성 장질환 치료제
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2013052813A1 (en) 2011-10-06 2013-04-11 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US10272133B2 (en) 2011-10-06 2019-04-30 Vanderbilt University Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
US8932559B2 (en) 2011-10-06 2015-01-13 Vanderbilt University Compositions and methods for preserving insulin-producing cells and insulin production and treating diabetes
US9388224B2 (en) * 2011-10-06 2016-07-12 Vanderbilt University Compositions for preserving insulin-producing cells and insulin production and treating diabetes
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
US9492544B2 (en) 2013-04-11 2016-11-15 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
KR102758333B1 (ko) 2013-08-28 2025-01-23 벡톤 디킨슨 앤드 컴퍼니 대량의 동시 단일 세포 분석
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
US10342847B2 (en) 2015-02-27 2019-07-09 Vanderbilt University Compositions and methods for preventing and reducing inflammation and treating disorders associated with inflammation
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
WO2016160844A2 (en) 2015-03-30 2016-10-06 Cellular Research, Inc. Methods and compositions for combinatorial barcoding
JP6940484B2 (ja) 2015-09-11 2021-09-29 セルラー リサーチ， インコーポレイテッド ライブラリー正規化のための方法および組成物
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
CN109791157B (zh) 2016-09-26 2022-06-07 贝克顿迪金森公司 使用具有条形码化的寡核苷酸序列的试剂测量蛋白质表达
CN110382708A (zh) 2017-02-01 2019-10-25 赛卢拉研究公司 使用阻断性寡核苷酸进行选择性扩增
CN110719959B (zh) 2017-06-05 2021-08-06 贝克顿迪金森公司 针对单细胞的样品索引
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
JP7358388B2 (ja) 2018-05-03 2023-10-10 ベクトン・ディキンソン・アンド・カンパニー 反対側の転写物末端における分子バーコーディング
CN112272710A (zh) 2018-05-03 2021-01-26 贝克顿迪金森公司 高通量多组学样品分析
EP3849591A4 (de) * 2018-09-14 2022-10-12 Vanderbilt University Verfahren und zusammensetzungen zur behandlung von hauterkrankungen
ES2992135T3 (es) 2018-10-01 2024-12-09 Becton Dickinson Co Determinar secuencias de transcripción 5’
US11932849B2 (en) 2018-11-08 2024-03-19 Becton, Dickinson And Company Whole transcriptome analysis of single cells using random priming
US11492660B2 (en) 2018-12-13 2022-11-08 Becton, Dickinson And Company Selective extension in single cell whole transcriptome analysis
ES2945227T3 (es) 2019-01-23 2023-06-29 Becton Dickinson Co Oligonucleótidos asociados con anticuerpos
WO2020167920A1 (en) 2019-02-14 2020-08-20 Cellular Research, Inc. Hybrid targeted and whole transcriptome amplification
CN120099137A (zh) 2019-07-22 2025-06-06 贝克顿迪金森公司 单细胞染色质免疫沉淀测序测定
JP7522189B2 (ja) 2019-11-08 2024-07-24 ベクトン・ディキンソン・アンド・カンパニー 免疫レパートリーシーケンシングのための完全長ｖ（ｄ）ｊ情報を得るためのランダムプライミングの使用
WO2021146219A1 (en) 2020-01-13 2021-07-22 Becton, Dickinson And Company Cell capture using du-containing oligonucleotides
US11649497B2 (en) 2020-01-13 2023-05-16 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and RNA
WO2021155057A1 (en) 2020-01-29 2021-08-05 Becton, Dickinson And Company Barcoded wells for spatial mapping of single cells through sequencing
BR112022011744A2 (pt) * 2020-02-18 2022-09-20 Cellivery Therapeutics Inc Peptídeo sintético inibidor de importação nuclear permeável à célula melhorado para inibição de tempestade de citocina ou doença inflamatória e uso do mesmo
WO2021173719A1 (en) 2020-02-25 2021-09-02 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
US11661625B2 (en) 2020-05-14 2023-05-30 Becton, Dickinson And Company Primers for immune repertoire profiling
US12157913B2 (en) 2020-06-02 2024-12-03 Becton, Dickinson And Company Oligonucleotides and beads for 5 prime gene expression assay
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
US12391940B2 (en) 2020-07-31 2025-08-19 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
EP4247967A1 (de) 2020-11-20 2023-09-27 Becton, Dickinson and Company Profilierung von stark exprimierten und schwach exprimierten proteinen
CN116685850A (zh) 2020-12-15 2023-09-01 贝克顿迪金森公司 单细胞分泌组分析
US20250302967A1 (en) * 2022-05-12 2025-10-02 Amytrx Therapeutics, Inc. Peptide formulations and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5191063A (en) * 1989-05-02 1993-03-02 University Of Medicine And Dentistry Of New Jersey Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5126323A (en) * 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
US5962415A (en) 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6323317B1 (en) * 1996-11-01 2001-11-27 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostics proteins comprising a SOCS box
EP1975234A2 (de) 1996-11-01 2008-10-01 The Walter And Eliza Hall Institute Of Medical Research Therapeutische und diagnostische Agenzien zur Modulierung der Zellreaktion auf Zytokine
US6090539A (en) * 1997-01-13 2000-07-18 Yale University Methods and compositions utilizing Rad51
WO1998034118A1 (en) 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
EP0970215A1 (de) 1997-11-03 2000-01-12 Incyte Pharmaceuticals, Inc. Cytokinsignal-suppressor
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
EP1224220A2 (de) 1999-10-21 2002-07-24 Smithkline Beecham Corporation Gen 1 der epo-primärantwort, eprg1
US6841535B2 (en) * 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use

Also Published As

Publication number Publication date
EP1246616B1 (de) 2006-08-02
KR20030025901A (ko) 2003-03-29
JP2003514852A (ja) 2003-04-22
US8324148B2 (en) 2012-12-04
EP1246616A4 (de) 2005-01-05
DE60029829D1 (de) 2006-09-14
AU783479B2 (en) 2005-11-03
US20040147435A1 (en) 2004-07-29
DE60029829T2 (de) 2007-03-01
EP1246616A1 (de) 2002-10-09
WO2001037821A1 (en) 2001-05-31
AU1933101A (en) 2001-06-04
US6495518B1 (en) 2002-12-17
CA2391943A1 (en) 2001-05-31
BR0015977A (pt) 2006-06-06

Similar Documents

Publication Publication Date Title
ATE334664T1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
DE69524448D1 (de) Fusogene liposomen
US20050080030A1 (en) Methods and compositions for enhancing the delivery of a nucleic acid to a cell
DE69923840D1 (de) Transfer von mRNAs unter Verwendung von polykationischen Verbindungen
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
BR9813202B1 (pt) complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes.
ATE359825T1 (de) J-kette und analoge für konjugate zielgerichtet auf epithelzellen
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ATE245697T1 (de) Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert
WO2005018544A8 (en) Therapy-enhancing glucan
DE69633725D1 (de) Kationische lipide/dns komplexe zum zielen von genen
DK0998501T3 (da) Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapi
Razin et al. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
TR200102985T2 (tr) Gen tedavisi teknikleri.
ES2240971T3 (es) Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.
TR200201119T2 (tr) İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA.
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
Kawase et al. Construction and characterization of a fusion protein with epidermal growth factor and the cell-binding domain of fibronectin
WO1999065461A3 (en) Cationic amphiphile micellar complexes
WO2001044198A8 (de) Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties